IQVIA (NYSE:IQV - Free Report) had its target price decreased by Truist Financial from $286.00 to $265.00 in a report released on Monday morning, Benzinga reports. Truist Financial currently has a buy rating on the medical research company's stock.
A number of other research analysts also recently commented on IQV. Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a report on Friday. Argus raised IQVIA to a "strong-buy" rating in a research note on Wednesday, July 31st. UBS Group lifted their price objective on IQVIA from $295.00 to $300.00 and gave the company a "buy" rating in a research report on Tuesday, July 23rd. StockNews.com upgraded IQVIA from a "hold" rating to a "buy" rating in a report on Wednesday, October 30th. Finally, Barclays reduced their price objective on IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research note on Friday. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $261.56.
Check Out Our Latest Stock Report on IQV
IQVIA Price Performance
IQV traded up $1.03 during trading on Monday, hitting $210.19. The company's stock had a trading volume of 2,084,364 shares, compared to its average volume of 1,092,160. The company has a current ratio of 0.81, a quick ratio of 0.85 and a debt-to-equity ratio of 1.76. The business's fifty day simple moving average is $233.55 and its 200 day simple moving average is $229.64. The firm has a market capitalization of $38.32 billion, a price-to-earnings ratio of 27.58, a P/E/G ratio of 2.01 and a beta of 1.51. IQVIA has a twelve month low of $190.20 and a twelve month high of $261.73.
Insider Transactions at IQVIA
In other news, insider Eric Sherbet sold 1,300 shares of the business's stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.60% of the company's stock.
Institutional Investors Weigh In On IQVIA
A number of institutional investors have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board lifted its position in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock worth $719,634,000 after purchasing an additional 211,653 shares during the period. Lazard Asset Management LLC lifted its position in shares of IQVIA by 0.9% during the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company's stock valued at $825,416,000 after acquiring an additional 30,014 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company's stock valued at $618,046,000 after acquiring an additional 86,870 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of IQVIA by 3.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company's stock valued at $634,927,000 after acquiring an additional 92,293 shares during the last quarter. Finally, Capital Research Global Investors lifted its position in shares of IQVIA by 7.2% during the 1st quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company's stock valued at $540,882,000 after acquiring an additional 143,533 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.
About IQVIA
(
Get Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
